[TCR peptide vaccination for autoimmune diseases: involvement of T-T interaction between autoimmune T cells presenting TCR peptide and CD4-CD8- regulatory T cells].
TCR peptide vaccination has been recently regarded as a future therapy for autoimmune diseases. In spite of the potential value, its underlying mechanisms have not been clearly established. M. F. Kozovska, T. Tabira and I have recently analyzed the immune regulation triggered by V beta 17a-50-68 peptide vaccine in SJL/J mice and desciribed a novel T-T interaction between encephalitogenic T cells presenting TCR peptide and CD4-CD8- regulatory T cells (Journal of Immunology 157:1781, 1996). In this brief review, I discuss how anti-idiotypic regulation can be triggered by the exogenous TCR peptide, and what we have learned from the animal experiments with regard to the natural regulation in human autoimmune diseases such as multiple sclerosis.
Yamamura
T
T
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D001327:Autoimmune Diseases / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D051379:Mice; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D011948:Receptors, Antigen, T-Cell